IGC Pharma (IGC) Other Non-Current Assets (2011 - 2026)
IGC Pharma (IGC) reported Other Non-Current Assets of $659000.0 for Q1 2026, down 3.23% year-over-year from $681000.0 in Q1 2025, and down 1.49% quarter-over-quarter from $669000.0 in Q4 2025.
IGC Pharma (IGC) Other Non-Current Assets (2011 - 2026) Analysis & Trends
IGC Pharma (IGC) has 16 years of Other Non-Current Assets data on file, last reported at $659000.0 in Q1 2026.
- Other Non-Current Assets for Q1 2026 came in at $659000.0, down 3.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $659000.0 (down 3.23% YoY), and the FY2026 annual result was $659000.0, down 3.23% from the prior year.
- Other Non-Current Assets declined to $659000.0 in Q1 2026 per IGC's latest filing, from $669000.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $1.0 million in Q4 2022 and troughed at $2000.0 in Q2 2024.
- A 5-year average of $780764.7 and a median of $688000.0 in 2024 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Assets sank 99.8% in 2024, then surged 33900.0% in 2025.
- A 5-year view of Other Non-Current Assets shows it stood at $1.0 million in 2022, then dropped by 2.82% to $999000.0 in 2023, then tumbled by 31.83% to $681000.0 in 2024, then slipped by 1.76% to $669000.0 in 2025, then fell by 1.49% to $659000.0 in 2026.
- Business Quant data shows IGC's Other Non-Current Assets at $659000.0 in Q1 2026, $669000.0 in Q4 2025, and $672000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 60,000.00 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | IGC Pharma | 28.11 Mn | 27.85 Mn | - | 659,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 659,000.00 |
| Dec 31, 2025 | 669,000.00 |
| Sep 30, 2025 | 672,000.00 |
| Jun 30, 2025 | 680,000.00 |
| Mar 31, 2025 | 681,000.00 |
| Dec 31, 2024 | 681,000.00 |
| Sep 30, 2024 | 687,000.00 |
| Jun 30, 2024 | 2,000.00 |
| Mar 31, 2024 | 688,000.00 |
| Dec 31, 2023 | 999,000.00 |
| Sep 30, 2023 | 998,000.00 |
| Jun 30, 2023 | 1.02 Mn |
| Mar 31, 2023 | 1.00 Mn |
| Dec 31, 2022 | 1.03 Mn |
| Sep 30, 2022 | 950,000.00 |
| Jun 30, 2022 | 922,000.00 |
| Mar 31, 2022 | 937,000.00 |
| Dec 31, 2021 | 612,000.00 |
| Sep 30, 2021 | 611,000.00 |
| Jun 30, 2021 | 596,000.00 |